Australia’s nutritional gummy market is expanding rapidly, but that growth also exposes a structural imbalance. According to Grand View Research, the category reached $251.3 million in 2023 and is projected to grow at a 15.8% CAGR from 2024 to 2030.
The Australian pharmaceutical market is expected to be worth billion by 2020, says GlobalData report
At the same time, the Complementary Medicines Australia (CMA) 2025 Industry Snapshot notes that Australia has 81 TGA-licensed complementary medicine manufacturing facilities … yet only a limited number are equipped for TGA-compliant gummy production, leaving a significant gap in regulated supply.
SIRIO Pharma is among the few suppliers capable of manufacturing TGA-compliant gummies. With facilities aligned with Australia’s TGA requirements, the company helps to address this shortage in regulated gummy manufacturing capacity.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Nutraceutical Business Review.
Subscribe now Already a subscriber? Sign in here.
